Detrusor Overactivity Clinical Trial
Official title:
Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity
In the last decade, several authors proposed ultrasound measurement of Bladder wall
thickness (BWT) for the screening of the voiding dysfunction and of the detrusor
overactivity (DO). The aims of the investigator prospective study were:
- to compare the ultrasonographic measurement of BWT in women with DO vs women with other
urodynamic diagnosis in a very large population.
- to verify whether the BWT in women with DO can be different in the clinically or
urodinamically different forms of DO.
n/a
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04543552 -
A Comparative Analysis of Portable Bladder Scanner to Determine Age/ Volume Specific Accuracy in 0-6 Years of Children
|
||
Completed |
NCT04978714 -
USI and/or DO in Women With Cystocele Before and After Cystocele Repair
|
||
Not yet recruiting |
NCT04693897 -
Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker
|
||
Enrolling by invitation |
NCT00822913 -
Botulinum A Toxin in Patients With Parkinson's Disease
|
Phase 4 | |
Terminated |
NCT00373789 -
Refractory Urge Incontinence and Botox Injections
|
Phase 3 | |
Completed |
NCT01093534 -
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
|
Phase 4 | |
Terminated |
NCT01023269 -
Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
|
N/A | |
Not yet recruiting |
NCT05572918 -
Developing a Simple Test to Diagnose Overactive Bladder
|
||
Completed |
NCT01850706 -
UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation
|
N/A | |
Completed |
NCT00478881 -
A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function
|
Phase 2 | |
Completed |
NCT00678795 -
A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis
|
Phase 3 |